Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Detection of TP53 mutations by immunohistochemistry in acute myeloid leukemia varies with interpreter expertise and mutation status.

American journal of clinical pathology - 9 Sept 2025

Richman Lee P, Waller Brianna F, Lovitch Scott B, Jambhekar Ashwini

Abstract excerpt

OBJECTIVE: TP53 mutations, including missense and inactivating (frameshift, splice site, and nonsense) mutations, occur in approximately 10% of myeloid neoplasms and confer adverse outcomes. Classification of myeloid neoplasms by World Health Organization and International Consensus Classification standards recognizes the importance of early detection of TP53 mutations. p53 immunohistochemistry (IHC) is a widely...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Mutational Analysis

Share to TP53 gene

Share to Immunohistochemistry

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 40414698
DOI: 10.1093/ajcp/aqaf047

Genes

TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Detection of TP53 mutations by immunohistochemistry in acute myeloid leukemia varies with interpreter expertise and mutation status.PMID 40414698Read ↗

Early identification of TP53 mutations and TP53 allelic state in myelodysplastic neoplasms and acute myeloid leukemia via point‐of‐care p53 immunohistochemistrySemantic proximity Read ↗

Immunohistochemistry screening for TP53 mutation in myeloid neoplasms in AZF-fixed bone marrow biopsies.Semantic proximity Read ↗

A clinical guide to TP53 mutations in myeloid neoplasms.Semantic proximity Read ↗

Correlation of p53 immunohistochemistry with TP53 mutational status and overall survival in newly diagnosed acute myeloid leukaemia.Semantic proximity Read ↗

TP53 mutations in myeloid neoplasms: implications for accurate laboratory detection, diagnosis, and treatment.Semantic proximity Read ↗

Utility of p53 immunohistochemistry as a surrogate for sequencing in myeloid neoplasms: A tale of caution.Semantic proximity Read ↗

p53 immunohistochemistry as an ancillary tool for rapid assessment of residual disease in TP53-mutated acute myeloid leukemia and myelodysplastic syndromes.Semantic proximity Read ↗

Immunohistochemistry for p53 is a useful tool to identify cases of acute myeloid leukemia with myelodysplasia-related changes that are TP53 mutated, have complex karyotype, and have poor prognosis.Semantic proximity Read ↗

Real-world routine diagnostic molecular analysis for TP53 mutational status is recommended over p53 immunohistochemistry in B-cell lymphomas.Semantic proximity Read ↗

TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia.Semantic proximity Read ↗

TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation.Semantic proximity Read ↗

Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.